The goal of this task order is to perform pharmacoepidemiology research and a PK, pharmacodynamic, pharmacogenomic, efficiency, and safety trial of the highest recommended dose of sildenafil in…
Active Awarded Last action
- Contract number
- 75N94022F00001
- Awardee
-
Duke University UEI TP7EK8DZV6N5
- Awarding agency
-
National Institute of Child Health and Human Development
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,457,295
Award facts
- Contract value 100% obligated
- $1,457,295.00 Current and potential, with all options
- Completion date 93% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost No Fee
- Place of performance
- Durham, NC 27705, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $1,457,295 |
About this award
This is a federal contract award from the National Institute of Child Health and Human Development (NICHD) to Duke University, a leading private research institution, to perform pharmacoepidemiology research and a pharmacokinetic, pharmacodynamic, pharmacogenomic, efficacy, and safety trial of the highest recommended dose of sildenafil in preterm neonates at risk of bronchopulmonary dysplasia. The goal is to assess the safety of sildenafil in premature infants. This is a non-severable task order contract valued at $1,457,295.00, with a performance period ending on February 14, 2027. The contract is not set aside. Duke University has a significant indefinite delivery contract (IDV) with NICHD for the Best Pharmaceuticals for Children Act Pediatric Trials Network, valued at up to $149 million, which supports a comprehensive program for pediatric drug development.
Description
The goal of this task order is to perform pharmacoepidemiology research and a PK, pharmacodynamic, pharmacogenomic, efficiency, and safety trial of the highest recommended dose of sildenafil in preterm neonates (cohort 3); with clinically relevant OU
Quick answers
Who was awarded contract 75N94022F00001?
75N94022F00001 was awarded to Duke University by National Institute of Child Health and Human Development (National Institutes of Health) on June 14, 2022.
How much is contract 75N94022F00001 worth?
The government has obligated $1,457,295 on 75N94022F00001.
Is contract 75N94022F00001 an order under another contract?
Yes. 75N94022F00001 is a delivery order under 75N94018D00003, an indefinite delivery contract.
Was contract 75N94022F00001 competed?
The extent of competition for 75N94022F00001 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award